{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"560"},{"groupId":"OG001","value":"86"},{"groupId":"OG002","value":"19"},{"groupId":"OG003","value":"10"}]}],"title":"Bortezomib and Lenalidomide (VR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"497"},{"groupId":"OG001","value":"99"},{"groupId":"OG002","value":"43"},{"groupId":"OG003","value":"18"}]}],"title":"Bortezomib and Cyclophosphamide (VC)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"272"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"11"}]}],"title":"Bortezomib and Thalidomide (VT)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"3"}]}],"title":"Bortezomib and Melphalan (VM)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"5"}]}],"title":"Lenalidomide (R)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"218"},{"groupId":"OG002","value":"126"},{"groupId":"OG003","value":"30"}]}],"title":"Lenalidomide and Dexamethasone (RD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"5"}]}],"title":"Cyclophosphamide and Thalidomide (CT)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"3"}]}],"title":"Melphalan and Thalidomide (MT)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"}]}],"title":"Thalidomide and Dexamethasone (TD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"47"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"6"}]}],"title":"Bortezomib and dexamethasone (VD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"96"},{"groupId":"OG002","value":"115"},{"groupId":"OG003","value":"34"}]}],"title":"Ixazomib and Lenalidomide (IR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"112"},{"groupId":"OG002","value":"42"},{"groupId":"OG003","value":"18"}]}],"title":"Carfilzomib and Lenalidomide (KR)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"6"}]}],"title":"Bortezomib and Pomalidomide (VPom)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"12"}]}],"title":"Carfilzomib and Pomalidomide (KPom)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"59"},{"groupId":"OG002","value":"76"},{"groupId":"OG003","value":"46"}]}],"title":"Carfilzomib and dexamethasone (KD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"110"},{"groupId":"OG002","value":"78"},{"groupId":"OG003","value":"46"}]}],"title":"Daratumumab-Bortezomib (dara-V)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"}]}],"title":"Daratumumab-Ixazomib (dara-I)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"149"},{"groupId":"OG002","value":"70"},{"groupId":"OG003","value":"31"}]}],"title":"Daratumumab-Lenalidomide (dara-R)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"72"},{"groupId":"OG003","value":"43"}]}],"title":"Daratumumab-Pomalidomide (dara-Pom)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"9"}]}],"title":"Ixazomib and Dexamethasone (ID)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"4"}]}],"title":"Ixazomib (I)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"66"},{"groupId":"OG003","value":"39"}]}],"title":"Pomalidomide and Dexamethasone (PomD)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"56"}]}],"title":"Daratumumab (Dara)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"10"}]}],"title":"Elotuzumab and Lenalidomide (Elo-R)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"14"}]}],"title":"Elotuzumab-Pomalidomide (Elo-Pom)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"}]}],"title":"Elotuzumab-Other Regimen (Elo-Other)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"416"},{"groupId":"OG001","value":"359"},{"groupId":"OG002","value":"390"},{"groupId":"OG003","value":"380"}]}],"title":"Other Regimen"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2195"},{"groupId":"OG001","value":"1685"},{"groupId":"OG002","value":"1279"},{"groupId":"OG003","value":"845"}],"units":"Participants"}],"groups":[{"description":"The most common treatment regimens prescribed in participants treated in 1st line of therapy were PI+IMiD, PI+AA, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG000","title":"1st Line of Therapy"},{"description":"The most common treatment regimens prescribed in participants treated in 2nd line of therapy were PI+IMiD, IMiD, and PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG001","title":"2nd Line of Therapy"},{"description":"The most common treatment regimens prescribed in participants treated in 3rd line of therapy were IMiD, PI+IMiD, and mAB+IMiD treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG002","title":"3rd Line of Therapy"},{"description":"The most common treatment regimens prescribed in participants treated in 4th line of therapy were mAb, mAb+IMiD, and mAB+PI treatment as part of their index regimen while enrolled in the study and were observed until study discontinuation, death or end of study (up to approximately 5 years).","id":"OG003","title":"4th Line of Therapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All Enrolled Population included all participants who signed the inform consent form. Participants were reported more than once in each line of therapy. Data is reported only for 1st, 2nd 3rd and 4th line of therapy. The overall number of participants analyzed is the number of participants available for analyses.","reportingStatus":"POSTED","timeFrame":"Baseline up to 5 years","title":"Number of Participants Receiving Different Treatment Combinations","type":"SECONDARY","unitOfMeasure":"Participants"}